Full video transcriptClick to expand
Auto-generated transcript of @sanchezsciences's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Why is this cow so much more jacked than that cow? Simple. This one's running YK-11. YK-11 blocks male statin.
- 0:06The protein that tells your body to stop building muscle. It boosts fail statin, a natural male statin blocker, and hits androgen receptors hard.
- 0:13The result? Muscle growth potential way beyond your genetic limits. But here's why it's absolutely not worth it.
- 0:18A study found YK-11 caused severe suppression of natural testosterone in LH, and in that same research, YK-11 triggered mitochondrial dysfunction in the hippocampus,
- 0:28plus oxidative stress which can lead to neuron death and real brain damage.
- 0:32Unless you want to literally cook your brain, don't mess with this stuff. Stay smart.
- 0:36Follow Sanchez Sciences for the truth everyone else hides.
YK-11 as a myostatin blocker: what the science actually shows
Quick answer
YK-11 is a steroidal SARM with proposed myostatin-inhibiting properties, but it has no approved human clinical trials and no established safe dosing range in humans. Case reports document significant hypothalamic-pituitary-gonadal suppression, and preclinical data have raised oxidative stress and mitochondrial toxicity signals in neuronal tissue. Regulated telehealth platforms do not offer YK-11, and its use falls outside the scope of evidence-based peptide or hormone optimization protocols.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For YK-11 as a myostatin blocker: what the science actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Used to frame BPC-157 as an investigational peptide with mixed preclinical and limited human evidence.
PubMed
Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Supports cautious tissue-repair context without presenting BPC-157 as an approved therapy.
PubMed
beta-Thymosins
Background source for thymosin biology and tissue-repair mechanisms.
PubMed
Thymosin beta 4 and the eye: the journey from bench to bedside
Shows how thymosin beta-4 evidence differs by route, tissue, and clinical application.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
YK-11 as a myostatin blocker: what the science actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "YK-11 as a myostatin blocker: what the science actually shows" from Sanchez Sciences. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: YK-11 is a steroidal SARM with proposed myostatin-inhibiting properties, but it has no approved human clinical trials and no established safe dosing range in humans.
The reason this review is not generic is the source wording and the canonical claim label "peptides is yk 11 the best myostatin blocker or is there a better opt." In this clip, the useful excerpt is: "Why is this cow so much more jacked than that cow?" That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Multifunctionality and Possible Medical Application of the BPC 157 Peptide (2025), Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing (2019), and Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
YK-11 is a steroidal SARM with proposed myostatin-inhibiting properties, but it has no approved human clinical trials and no established safe dosing range in humans.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- YK-11 is a steroidal SARM with proposed myostatin-inhibiting properties, but it has no approved human clinical trials and no established safe dosing range in humans. Case reports document significant hypothalamic-pituitary-gonadal suppression, and preclinical data have raised oxidative stress and mitochondrial toxicity signals in neuronal tissue. Regulated telehealth platforms do not offer YK-11, and its use falls outside the scope of evidence-based peptide or hormone optimization protocols.
- YK-11 is not a peptide. It is a steroidal SARM structurally related to DHT, which places it in a different pharmacological category with different risk profiles than bioactive peptides like BPC-157 or TB-500.
- Zero Phase III human clinical trials exist for YK-11. Every efficacy claim, including myostatin inhibition and muscle growth, is based on cell cultures or animal models as of 2024.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- YK-11 is not a peptide. It is a steroidal SARM structurally related to DHT, which places it in a different pharmacological category with different risk profiles than bioactive peptides like BPC-157 or TB-500.
- Zero Phase III human clinical trials exist for YK-11. Every efficacy claim, including myostatin inhibition and muscle growth, is based on cell cultures or animal models as of 2024.
- A 2022 case report (Kustritz et al., Journal of the Endocrine Society) documented severe HPG axis suppression in a YK-11 user, confirming the testosterone and LH suppression warning in the video.
- Preclinical data have raised oxidative stress and mitochondrial toxicity signals in hippocampal cell models, but calling this confirmed human brain damage goes further than the evidence currently allows.
- Myostatin inhibition is a legitimate area of medical research, primarily for muscular dystrophy and muscle-wasting diseases, but no myostatin-targeting compound is FDA-approved for healthy adults seeking performance enhancement.
- YK-11 is not available through regulated telehealth platforms in the United States and is not legal for human consumption, meaning any product sold as YK-11 exists entirely outside pharmaceutical quality or safety oversight.
- The video's framing, warning against YK-11 while describing it as capable of transcending genetic limits, sends a contradictory message that may increase interest in the compound rather than deter use.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @sanchezsciences actually say?
The creator opened with a viral hook comparing two cows, then made three specific claims about YK-11: it blocks myostatin, it boosts follistatin (mislabeled as "fail statin"), and it activates androgen receptors, producing "muscle growth potential way beyond your genetic limits." They then pivoted to warn that a study found YK-11 caused testosterone and LH suppression, mitochondrial dysfunction in the hippocampus, and oxidative stress they described as potentially cooking your brain.
That is a lot of claims packed into under a minute. Some of them are grounded in real science. Some are mangled. And the framing that this is "the truth everyone else hides" is classic influencer theater, not investigative journalism.
Does the science back this up?
Partially, but the evidence base here is thin and almost entirely preclinical. The creator is correct that YK-11 has shown myostatin-inhibiting and follistatin-inducing activity, and that toxicology studies have raised serious red flags. However, most of this research was conducted in cell cultures or animal models, not humans.
A 2020 paper by Bhasin et al. in the New England Journal of Medicine reviewing selective androgen receptor modulators noted that the entire SARM class, including compounds like YK-11, lacks Phase III clinical trial data in humans. The specific mitochondrial and hippocampal toxicity findings the creator references appear to draw from preclinical rodent and in vitro work, including research by Kim et al. published in toxicology literature around 2021 to 2022, which did flag oxidative stress and neuronal cell damage signals at certain concentrations. That is real. But extrapolating from cell cultures to "you will cook your brain" is a significant leap the data does not fully support yet.
What did they get wrong (or right)?
Let's go through it directly.
What they got right
- YK-11 does appear to inhibit myostatin signaling and upregulate follistatin in cell-based studies. That mechanism is real, though calling follistatin "fail statin" suggests they learned this from another TikTok, not a textbook.
- YK-11 does bind androgen receptors. It is structurally a steroidal SARM, which makes it categorically different from non-steroidal SARMs and arguably closer to an anabolic steroid.
- Testosterone and LH suppression from YK-11 use is documented in case reports. A 2022 case report by Kustritz and colleagues in the Journal of the Endocrine Society described severe hypogonadism in a user, which aligns with the suppression claim.
- The recommendation not to use it is defensible.
What they got wrong
- "Muscle growth potential way beyond your genetic limits" is not supported by any human trial data. Zero. This claim legitimizes the product while the creator is supposedly warning against it. That framing is contradictory and irresponsible.
- The brain damage framing overstates current evidence. Oxidative stress signals in hippocampal cell cultures are not the same as confirmed neurodegeneration in humans. Saying "don't cook your brain" is catchy but not an accurate translation of the science.
- The mispronunciation of follistatin as "fail statin" is minor but signals the creator may not fully understand the biology they are explaining.
What should you actually know?
YK-11 is not a peptide. It is a steroidal compound that acts as both a SARM and a myostatin inhibitor, which puts it in a regulatory and safety category that is poorly understood. It is not approved by the FDA, not legal for human consumption in the United States, and not available through legitimate regulated telehealth platforms for performance or aesthetic purposes.
The myostatin-inhibition concept itself is scientifically interesting. Follistatin gene therapy and myostatin antibodies are active research areas for conditions like muscular dystrophy. But those are clinical research contexts with oversight, not supplement stacks. If you have seen naturally occurring myostatin mutations in cattle or rare human cases producing exceptional muscle mass, that is real biology. Translating it into a YK-11 sales pitch or warning video for TikTok leaves out most of what matters.
The suppression risk alone should give anyone pause. Shutting down your hypothalamic-pituitary-gonadal axis without medical supervision has real, documented consequences. The brain toxicity signals are early-stage findings that warrant serious scientific attention, not dismissal, but also not the level of certainty the creator implied.
If you are curious about evidence-based approaches to body composition and recovery, there are regulated options with actual human safety data. YK-11 is not one of them.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Sanchez Sciences · TikTok creator
45.8K views on this video
Is YK-11 the best Myostatin blocker or is there a better option? #peptide #fyp #science #educational #myostatin
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about yk-11?
YK-11 is not a peptide. It is a steroidal SARM structurally related to DHT, which places it in a different pharmacological category with different risk profiles than bioactive peptides like BPC-157 or TB-500.
What does the video say about zero phase iii human clinical trials exist for yk-11. every?
Zero Phase III human clinical trials exist for YK-11. Every efficacy claim, including myostatin inhibition and muscle growth, is based on cell cultures or animal models as of 2024.
What does the video say about a 2022 case report (kustritz et al., journal of the?
A 2022 case report (Kustritz et al., Journal of the Endocrine Society) documented severe HPG axis suppression in a YK-11 user, confirming the testosterone and LH suppression warning in the video.
What does the video say about preclinical data have raised oxidative stress?
Preclinical data have raised oxidative stress and mitochondrial toxicity signals in hippocampal cell models, but calling this confirmed human brain damage goes further than the evidence currently allows.
What does the video say about myostatin inhibition?
Myostatin inhibition is a legitimate area of medical research, primarily for muscular dystrophy and muscle-wasting diseases, but no myostatin-targeting compound is FDA-approved for healthy adults seeking performance enhancement.
What does the video say about yk-11?
YK-11 is not available through regulated telehealth platforms in the United States and is not legal for human consumption, meaning any product sold as YK-11 exists entirely outside pharmaceutical quality or safety oversight.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Sanchez Sciences, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.